Compare SILC & BDSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SILC | BDSX |
|---|---|---|
| Founded | 1987 | 2005 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Computer Manufacturing | Precision Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 86.3M | 88.3M |
| IPO Year | 1994 | 2020 |
| Metric | SILC | BDSX |
|---|---|---|
| Price | $18.74 | $11.33 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | N/A | ★ $32.50 |
| AVG Volume (30 Days) | 81.2K | ★ 276.7K |
| Earning Date | 01-29-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $61,926,000.00 | ★ $80,173,000.00 |
| Revenue This Year | $17.17 | $22.01 |
| Revenue Next Year | $12.28 | $26.81 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 6.56 | ★ 22.29 |
| 52 Week Low | $12.44 | $3.44 |
| 52 Week High | $23.00 | $20.40 |
| Indicator | SILC | BDSX |
|---|---|---|
| Relative Strength Index (RSI) | 54.35 | 57.37 |
| Support Level | $18.55 | $9.83 |
| Resistance Level | $21.22 | $11.00 |
| Average True Range (ATR) | 1.86 | 1.13 |
| MACD | -0.07 | -0.07 |
| Stochastic Oscillator | 46.48 | 69.05 |
Silicom Ltd designs and manufactures networking and data infrastructure solutions for various servers, server-based systems, and communications devices. Its product categories consist of Server Adapters, Edge Networking Solutions, FPGA-Based Cards, x86 Open Appliances, Bypass Switches, and TAPs. Geographically, it derives a majority of its revenue from North America and also has a presence in Europe and Asia-Pacific.
Biodesix Inc is a diagnostic solutions company with a focus in lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Covid tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics.